X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
tezosentan (114) 114
humans (94) 94
index medicus (66) 66
cardiac & cardiovascular systems (61) 61
animals (57) 57
heart failure (55) 55
male (50) 50
randomized intravenous tezosentan (49) 49
endothelin receptor antagonists (48) 48
female (48) 48
heart failure - drug therapy (40) 40
endothelin (39) 39
pharmacology & pharmacy (32) 32
pyridines - therapeutic use (32) 32
acute disease (31) 31
tetrazoles - therapeutic use (31) 31
double-blind (30) 30
pyridines - pharmacology (30) 30
tetrazoles - pharmacology (30) 30
heart failure - physiopathology (27) 27
vasodilator agents - therapeutic use (24) 24
drug therapy (23) 23
pulmonary hypertension (23) 23
vasodilator agents - pharmacology (23) 23
treatment outcome (22) 22
aged (20) 20
double-blind method (20) 20
middle aged (20) 20
mortality (20) 20
bosentan (19) 19
receptor antagonist (19) 19
clinical trials (18) 18
swine (18) 18
infusions, intravenous (17) 17
acute heart failure (16) 16
blood pressure - drug effects (16) 16
dose-response relationship, drug (16) 16
endothelin-1 (16) 16
hemodynamics - drug effects (16) 16
hypertension (16) 16
hypertension, pulmonary - drug therapy (16) 16
outcomes (16) 16
research (16) 16
antagonist (15) 15
prognosis (15) 15
adult (14) 14
cardiovascular (14) 14
endothelin a receptor antagonists (14) 14
heart failure - mortality (14) 14
acute coronary syndromes (13) 13
acute myocardial-infarction (13) 13
chronic heart-failure (13) 13
endothelin receptor antagonist (13) 13
hemodynamics (13) 13
pharmacokinetics (13) 13
rats (13) 13
clinical trials as topic (12) 12
clinical-trials update (12) 12
heart failure - therapy (12) 12
pyridines - administration & dosage (12) 12
tetrazoles - administration & dosage (12) 12
care and treatment (11) 11
disease models, animal (11) 11
heart failure - diagnosis (11) 11
hypertension, pulmonary - physiopathology (11) 11
levosimendan (11) 11
nesiritide (11) 11
peripheral vascular disease (11) 11
pulmonary arterial-hypertension (11) 11
sepsis (11) 11
time factors (11) 11
blockade (10) 10
cardiac patients (10) 10
dosage and administration (10) 10
endothelin-1 - blood (10) 10
natriuretic peptide (10) 10
pyridines - pharmacokinetics (10) 10
surgery (10) 10
tetrazoles - pharmacokinetics (10) 10
therapy (10) 10
vascular resistance - drug effects (10) 10
vasoconstriction (10) 10
anesthesiology (9) 9
association (9) 9
cardiovascular agents - therapeutic use (9) 9
congestive heart failure (9) 9
heart-failure (9) 9
medicine & public health (9) 9
medicine, general & internal (9) 9
nitric-oxide (9) 9
pulmonary-hypertension (9) 9
pyridines - adverse effects (9) 9
tetrazoles - adverse effects (9) 9
blood-pressure (8) 8
cardiovascular disease (8) 8
cardiovascular diseases - drug therapy (8) 8
endothelin-1 - physiology (8) 8
expression (8) 8
heart failure - metabolism (8) 8
infusion (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ISSN 0735-1097, 11/2008, Volume 52, Issue 19, pp. 1540 - 1545
Objectives This study sought to assess the acute hemodynamic effect of vasopressin V-2 receptor antagonism. Background In decompensated heart failure (HF),... 
heart failure | vasopressin antagonists | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTAGONIST | PLASMA ARGININE VASOPRESSIN | hemodynamics | TEZOSENTAN
Journal Article
Journal of Surgical Research, ISSN 0022-4804, 11/2009, Volume 157, Issue 1, pp. e7 - e13
Background: Renal injury induced by aortic ischemia-reperfusion (IR) is an important factor in the development of postoperative acute renal failure following... 
tezosentan | abdominal aorta | renal injury | ischemia-reperfusion
Journal Article
Journal Article
American Heart Journal, ISSN 0002-8703, 2005, Volume 150, Issue 1, pp. 46 - 53
Journal Article
Journal Article
Clinical Biochemistry, ISSN 0009-9120, 09/2018, Volume 59, pp. 25 - 30
Serum concentration of big endothelin-1 (ET-1) has prognostic significance in heart failure. However, its prognostic value in cardiac resynchronization therapy... 
Cardiac resynchronization therapy | Big endothelin-1 | Risk factor | C-REACTIVE PROTEIN | CAPACITY | SYMPTOMS | PULMONARY ARTERIAL | EXERCISE | ATRIAL-FIBRILLATION | TRIAL | HEART-FAILURE PATIENTS | PREDICTORS | MEDICAL LABORATORY TECHNOLOGY | TEZOSENTAN
Journal Article
Journal Article
Hypertension, ISSN 0194-911X, 12/2019, Volume 74, Issue 6, pp. 1232 - 1265
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2017, Volume 120, Issue 3, pp. 505 - 508
Journal Article
JAMA, The Journal of the American Medical Association, ISSN 0098-7484, 11/2007, Volume 298, Issue 17
A study is conducted to find if endothelin receptor antagonist tezosentan improves outcomes in patients with acute heart failure. The results suggest that... 
Heart failure | Endothelin | Research | Tezosentan
Journal Article
Journal Article